Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants
- PMID: 16124003
- DOI: 10.1002/pbc.20565
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants
Abstract
Background: Malignant peripheral nerve sheath tumors (MPNSTs) occur most frequently in patients with neurofibromatosis type 1 and are often fatal. Current therapy relies upon radical surgical resection, which often fails to completely remove the tumor. To address the need for novel treatment approaches for this disease, we sought to determine if human MPNST-derived cell lines are sensitive to oncolytic Herpes simplex virus (oHSV) infection. Activation of the Ras pathway and its inhibitory effects on protein kinase R (PKR) activation have been shown to dictate cellular permissivity to oHSV mutants. Because NF-1-associated MPNSTs possess inherent hyperactive Ras, we hypothesized these tumors would be ideal therapeutic targets for oHSVs.
Procedure: Human MPNST-derived cell lines were examined for sensitivity to oHSV-mediated gene transduction, virus replication, cytotoxicity, and apoptosis. These parameters were correlated with PKR activation following oHSV infection and compared with normal human Schwann cells (NHSCs) without hyperactive Ras.
Results: MPNST-derived cell lines were efficiently transduced, supported virus replication and were killed by the oncolytic HSV mutants, including sporadic MPNSTs without hyperactive Ras. In contrast to the highly sensitive MPNST cell lines, NHSCs did not support mutant virus replication.
Conclusions: MPNSTs are susceptible to lysis by oncolytic HSV mutants, regardless of Ras status. Tumor-selective virus replication in MPNST cells appears to be mediated by both cellular expression of ribonucleotide reductase and prevention of eIF2alpha phosphorylation. Virus-induced cytotoxicity of MPNST cell lines was caused by both direct lysis and apoptosis. Our data suggest the use of oncolytic HSV mutants may represent a novel treatment approach for patients with MPNSTs.
(c) 2005 Wiley-Liss, Inc.
Similar articles
-
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.Mol Ther. 2007 Feb;15(2):279-86. doi: 10.1038/sj.mt.6300038. Mol Ther. 2007. PMID: 17235305
-
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.Clin Cancer Res. 2006 Nov 15;12(22):6791-9. doi: 10.1158/1078-0432.CCR-06-0263. Clin Cancer Res. 2006. PMID: 17121900
-
Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors.Oncogene. 2005 Aug 25;24(36):5589-605. doi: 10.1038/sj.onc.1208730. Oncogene. 2005. PMID: 15897877
-
Herpes simplex virus 1 (HSV-1) for cancer treatment.Cancer Gene Ther. 2006 Nov;13(11):975-92. doi: 10.1038/sj.cgt.7700946. Epub 2006 Apr 7. Cancer Gene Ther. 2006. PMID: 16604059 Review.
-
Reovirus - possible therapy of cancer.Neoplasma. 2006;53(6):457-62. Neoplasma. 2006. PMID: 17167712 Review.
Cited by
-
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10. J Clin Invest. 2013. PMID: 23221341 Free PMC article. Clinical Trial.
-
Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression.PLoS One. 2011 May 11;6(5):e19530. doi: 10.1371/journal.pone.0019530. PLoS One. 2011. PMID: 21589655 Free PMC article.
-
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.Mol Ther. 2008 May;16(5):879-85. doi: 10.1038/mt.2008.49. Epub 2008 Mar 25. Mol Ther. 2008. PMID: 18388918 Free PMC article.
-
Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Expert Opin Orphan Drugs. 2016;4(2):129-138. doi: 10.1517/21678707.2016.1128322. Epub 2015 Dec 26. Expert Opin Orphan Drugs. 2016. PMID: 27867771 Free PMC article.
-
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.J Immunother Cancer. 2022 Mar;10(3):e004410. doi: 10.1136/jitc-2021-004410. J Immunother Cancer. 2022. PMID: 35338089 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials